Editas Medicine Inc. (NASDAQ:EDIT)’s share price was down 2.4% during trading on Thursday . The company traded as low as $24.68 and last traded at $24.77, with a volume of 89,957 shares changing hands. The stock had previously closed at $25.37.

A number of equities analysts have recently commented on EDIT shares. Vetr raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 target price on the stock in a report on Monday, May 9th. Zacks Investment Research cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Wednesday, May 18th. Jefferies Group reaffirmed a “hold” rating and issued a $35.00 target price on shares of Editas Medicine in a report on Friday, June 10th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $33.50.

The stock’s 50-day moving average is $29.34 and its 200 day moving average is $30.54. The stock’s market cap is $872.00 million.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.50. The company earned $0.80 million during the quarter, compared to analyst estimates of $1.08 million. Equities analysts anticipate that Editas Medicine Inc. will post ($2.35) earnings per share for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.